2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/30/15FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
ROCKVILLE, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-111, the Company’s investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I (MPS I). "The Rare Pediatric Dis... 
Printer Friendly Version
12/18/15REGENXBIO Added to Russell 2000® Index
ROCKVILLE, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc.  (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced the company was added to the Russell 2000® Index as part of Russell Investments’ quarterly addition of initial public offering companies. REGENXBIO joined the index after the NASDAQ market closed on December 18, 2015 . The ... 
Printer Friendly Version
12/01/15REGENXBIO to Participate in Upcoming Investor and Scientific Conferences
ROCKVILLE, Md., Dec. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that President and CEO Kenneth T. Mills will participate in the following upcoming investor and scientific conferences: 27th Annual Piper Jaffray Healthcare Conference Date: Tuesday, December 1, 2015 Location: New York Palace Hotel Gene Th... 
Printer Friendly Version
11/05/15REGENXBIO Reports Third Quarter 2015 Results
Closed Initial Public Offering Raising $145.2 Million in Net Proceeds ROCKVILLE, Md., Nov. 5, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today reported recent operational highlights and financial results for the quarter ended September 30, 2015. "So far, 2015 has been a truly transformative year for REGENXBIO and we look forward to... 
Printer Friendly Version
10/15/15Dr. David C. Stump Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., Oct. 15, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board of directors. "David's expertise in clinical research and development, as well as his experience advancing therapies through the regulatory process to FDA approval, will be of great value as REGENXBIO prepares to advance gene therapy treatments into the clinic," said Don Hayden, Chairman of REGEN... 
Printer Friendly Version
10/01/15FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
ROCKVILLE, Md., Oct. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (REGENXBIO) (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REGENXBIO's investigational gene therapy product candidate RGX-111 for the treatment of mucopolysaccharidosis Type I (MPS I). "REGENXBIO is pleased to have received Orphan Drug Designation from the FDA for RGX-111," said Kenneth T. Mills, President and... 
Printer Friendly Version
09/22/15REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to REGENXBIO were approximately ... 
Printer Friendly Version
09/16/15REGENXBIO Announces Pricing of Initial Public Offering
ROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled t... 
Printer Friendly Version
06/11/15REGENXBIO Enters Into Strategic Manufacturing Collaboration with Wuxi Apptec
ROCKVILLE, MD, AND SHANGHAI, JUNE 11, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into an exclusive strategic manufacturing collaboration with WuXi AppTec, Inc (WuXi). WuXi is a leading technology platform company that provides clients with a broad and integrated portfolio of laboratory and manufacturing services, including expertise in characterization and analysis of biologics. Through this collaboration, REGENXBIO plans to establ... 
Printer Friendly Version
05/27/15Dr. Jerry Karabelas Appointed to REGENXBIO Board of Directors
ROCKVILLE, MD, May 27, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the appointment of Jerry Karabelas, Ph.D., to its board of directors. “Jerry is an experienced biopharmaceutical leader who brings to REGENXBIO more than 20 years of success in key strategic, operational, commercial, research and development, and board roles," said Don Hayden, Chairman of REGENXBIO’s board of directors. “We are excited to have Jerry join the board at this important poin... 
Printer Friendly Version
05/20/15REGENXBIO Secures $70.5 Million in a Mezzanine Financing
AAV gene therapy leader builds investor syndicate that includes leading biotech and mutual funds to help advance its growing pipeline of novel treatmentsROCKVILLE, MD, May 20, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the successful completion of a heavily oversubscribed $70.5 million Series D financing.  The Series D brings the total capital raised since inception to more than $110 million.The Series D was led by new investor Vivo Capital and existi... 
Printer Friendly Version
04/28/15Luke M. Beshar Appointed to REGENXBIO Board of Directors
ROCKVILLE, MD, April 28, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that Luke M. Beshar has been appointed to its board of directors effective April 15. Mr. Beshar will serve as the chairman of REGENXBIO’s audit committee.“Luke’s strategic insights and deep financial expertise have contributed directly to the success of several biopharma companies,” said Don Hayden, Chairman of REGENXBIO’s board of directors. “His perspective and experience will be vi... 
Printer Friendly Version
04/23/15REGENXBIO and Dimension Therapeutics Add Development of Treatments for Two Metabolic Diseases to Exclusive Licensing Agreement
ROCKVILLE, MD April 23, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has added the indications of ornithine transcarbamylase deficiency (OTC) and Glycogen Storage Disease Type 1a (GSD1a) to its existing license agreement with Dimension Therapeutics.  This will enable Dimension to develop and commercialize products to treat OTC and GSD1a – as well as hemophilia A and B, which Dimension licensed from REGENXBIO in 2013 – using REGENXBIO’s proprieta... 
Printer Friendly Version
04/08/15 REGENXBIO Licenses Key Technologies from University of Pennsylvania and University of Minnesota for the Development of Treatments for MPS I and MPS II
WASHINGTON, DC April 8, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into separate license and research agreements with the University of Pennsylvania (Penn) and University of Minnesota (U of M) related to the delivery of AAV vectors for the treatment of MPS I and MPS II, also known as Hurler syndrome and Hunter syndrome, respectively. These agreements provide REGENXBIO with exclusive access to key technologies and resources that the... 
Printer Friendly Version
01/21/15REGENXBIO Raises $30 Million in Series C Financing
Proceeds to enable clinical development of lead gene therapy programs, expansion of clinical and manufacturing capabilitiesWASHINGTON, DC January 21, 2015 – REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the completion of a $30 million Series C financing. Venrock and Brookside Capital led the financing with participation from Deerfield Management and an unnamed new investor.  The company’s existing investors, FoxKiser and Fidelity BioSciences, also particip... 
Printer Friendly Version